EQUITIES 4 minutes to read

NY Open: Drugs can’t ease Wall Street’s Apple fears

Summary:  Traders may have dismissed the Asia “Twilight Zone Flash Crash” as just an anomaly in an extremely thin market, but even a big-ticket pharma takeover hasn't brightened the mood much.


Echo’s from Apple’s (AAP: Nasdaq) bombshell earnings forecast downgrade reverberated on Wall Street this morning. The Dow Jones Industrial Average opened in negative territory and had dropped 1.43% by 14:00 GMT. The S&P 500 followed suit, losing 1.44% while the Nasdaq shed 1.92%.  

What do you do if you have an extra $34.8 billion in cash lying around? If you are Bristol Meyers Squibb (BMY: NYSE), you buy (merge) with Celgene Corporation (CELG: Nasdaq). BMY: NYSE announced that it had entered into a definitive merger agreement with CELG: Nasdaq for $50.00 per share in cash and one BMY share. The press release touts compelling strategic and financial benefits as the rationale for the deal. CELG shareholders were impressed, and the stock rose 27.8% at the open. BMY shareholders were not nearly as thrilled, and that share price dropped 12.30% in early New York trading.

New York traders appear to have dismissed the Asia “Twilight Zone Flash Crash” as just an anomaly in an extremely thin market, one that is notorious for dramatic and unjustified price activity. The commodity bloc currencies are higher than where they closed as are EUR and the Swiss franc. USDJPY is the laggard as falling US Treasury yields weigh on the currency.

The US dollar is being undermined by mixed to soft economic data. The fickle ADP employment report surprised to the topside while the more important ISM Manufacturing PMI for December disappointed.

USDCAD appears to have re-correlated itself with West Texas Intermediate prices dropping from an overnight peak of 1.3657 to 1.3509 after the ISM report.  WTI rallied from an overnight low of $45.39/barrel to $$7.47/b before falling back to $46.58 in NY. Traders are encouraged by the double bottom at $42.60/b, an improved dialogue to the US/China trade talks and the onset of the Opec production cuts.
Chart: USDCAD 30 minute with WTI oil.     Source: Saxo Bank
Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)